Cargando…
Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease
Background: Currently there are no known cures and few effective treatments for mitochondrial disorders. It is also true there is a lack of knowledge about suitable clinician rated outcomes and how these change over time in this patient cohort. Objective: We sought to evaluate the validity and respo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271457/ https://www.ncbi.nlm.nih.gov/pubmed/27858729 http://dx.doi.org/10.3233/JND-140061 |
_version_ | 1782501357171769344 |
---|---|
author | Newman, Jane Galna, Brook Jakovljevic, Djordje G. Bates, Matthew G. Schaefer, Andrew M. McFarland, Robert Turnbull, Douglass M. Trenell, Michael I. Taylor, Robert W. Rochester, Lynn Gorman, Gráinne S. |
author_facet | Newman, Jane Galna, Brook Jakovljevic, Djordje G. Bates, Matthew G. Schaefer, Andrew M. McFarland, Robert Turnbull, Douglass M. Trenell, Michael I. Taylor, Robert W. Rochester, Lynn Gorman, Gráinne S. |
author_sort | Newman, Jane |
collection | PubMed |
description | Background: Currently there are no known cures and few effective treatments for mitochondrial disorders. It is also true there is a lack of knowledge about suitable clinician rated outcomes and how these change over time in this patient cohort. Objective: We sought to evaluate the validity and responsiveness to change of clinician rated outcome measures in patients with m.3243A>G-related mitochondrial disease. Methods: We assessed the six minute timed walk (6MTW), 10 meter walk / test (10MWT), Timed up and Go (TUG) and the 5 times sit to stand (5XSTS), in 18 patients (12 sedentary controls), at baseline and a subgroup of 10 control-matched patients following a 16-week structured aerobic exercise intervention program. Results: All outcome measures assessed were valid and able to differentiate between patients and controls. Disease severity, as measured by the Newcastle Mitochondrial Disease Adult Scale, correlated with TUG (r = 0.54, p = 0.020) and 10MWT (r = 0.47, p = 0.050). Receiver Operating Curve analysis revealed 5XSTS to be the most responsive measure (AUC 0.931; 95% CI 0.84– 1.00) with responsiveness to change, post intervention, emulating disease burden variance. Conclusions: The 5XSTS can be used to discriminate between mitochondrial patients and sedentary controls with high accuracy. The 10MWT and TUG may serve as suitable and clinically relevant clinician rated measures to track disease progression and assess intervention. |
format | Online Article Text |
id | pubmed-5271457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52714572017-01-30 Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease Newman, Jane Galna, Brook Jakovljevic, Djordje G. Bates, Matthew G. Schaefer, Andrew M. McFarland, Robert Turnbull, Douglass M. Trenell, Michael I. Taylor, Robert W. Rochester, Lynn Gorman, Gráinne S. J Neuromuscul Dis Research Report Background: Currently there are no known cures and few effective treatments for mitochondrial disorders. It is also true there is a lack of knowledge about suitable clinician rated outcomes and how these change over time in this patient cohort. Objective: We sought to evaluate the validity and responsiveness to change of clinician rated outcome measures in patients with m.3243A>G-related mitochondrial disease. Methods: We assessed the six minute timed walk (6MTW), 10 meter walk / test (10MWT), Timed up and Go (TUG) and the 5 times sit to stand (5XSTS), in 18 patients (12 sedentary controls), at baseline and a subgroup of 10 control-matched patients following a 16-week structured aerobic exercise intervention program. Results: All outcome measures assessed were valid and able to differentiate between patients and controls. Disease severity, as measured by the Newcastle Mitochondrial Disease Adult Scale, correlated with TUG (r = 0.54, p = 0.020) and 10MWT (r = 0.47, p = 0.050). Receiver Operating Curve analysis revealed 5XSTS to be the most responsive measure (AUC 0.931; 95% CI 0.84– 1.00) with responsiveness to change, post intervention, emulating disease burden variance. Conclusions: The 5XSTS can be used to discriminate between mitochondrial patients and sedentary controls with high accuracy. The 10MWT and TUG may serve as suitable and clinically relevant clinician rated measures to track disease progression and assess intervention. IOS Press 2015-06-04 /pmc/articles/PMC5271457/ /pubmed/27858729 http://dx.doi.org/10.3233/JND-140061 Text en IOS Press and the authors. All rights reserved This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License. |
spellingShingle | Research Report Newman, Jane Galna, Brook Jakovljevic, Djordje G. Bates, Matthew G. Schaefer, Andrew M. McFarland, Robert Turnbull, Douglass M. Trenell, Michael I. Taylor, Robert W. Rochester, Lynn Gorman, Gráinne S. Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title | Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title_full | Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title_fullStr | Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title_full_unstemmed | Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title_short | Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease |
title_sort | preliminary evaluation of clinician rated outcome measures in mitochondrial disease |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271457/ https://www.ncbi.nlm.nih.gov/pubmed/27858729 http://dx.doi.org/10.3233/JND-140061 |
work_keys_str_mv | AT newmanjane preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT galnabrook preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT jakovljevicdjordjeg preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT batesmatthewg preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT schaeferandrewm preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT mcfarlandrobert preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT turnbulldouglassm preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT trenellmichaeli preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT taylorrobertw preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT rochesterlynn preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease AT gormangrainnes preliminaryevaluationofclinicianratedoutcomemeasuresinmitochondrialdisease |